How I Made $5000 in the Stock Market

These Stocks Moved the Most Today: Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More

Dec 29, 2025 05:56:00 -0500 by Mackenzie Tatananni | #Technology

Traders working at the New York Stock Exchange. (NYSE)

Key Points

Stocks fell Monday, putting the so-called Santa Claus rally in jeopardy during a holiday-shortened trading week for Wall Street.

These stocks made notable moves:

Tesla declined 3.3%. Investors are focused on the electric-vehicle maker’s robo-taxi prospects, which have boosted the stock 14% this year. The stock is likely to finish higher in 2025. It has only fallen twice on a full-year basis since going public in 2010.

Shares of Nvidia , the top supplier of artificial-intelligence chips, fell 1.2%. Nvidia gained 1% on Friday and 5.3% last week after the company entered into a nonexclusive agreement to license technology from Groq, an AI chip start-up. The deal is reported to be worth about $20 billion.

Newmont tumbled 5.6%, making it the worst-performing stock in the S&P 500 , as shares of the world’s largest gold miner followed the prices of precious metals lower. Gold futures were down 4.5%.

Freeport-McMoRan , a miner of gold and copper, fell 2.9%. Silver prices hit an all-time high in overnight trading before pulling back sharply.

DigitalBridge Group climbed 9.6% to $15.26 after Japan’s SoftBank Group announced it was buying the data-center investment firm for a total enterprise value of roughly $4 billion, or $16 a share in cash. DigitalBridge shares rose as much as 35% in premarket trading before the deal was announced.

Devon Energy rose 1.4%, while APA Corp. and Halliburton were up 0.8% and 0.7%, respectively. Oil prices traded higher after U.S. talks with Ukraine on ending the war with Russia concluded without an agreement. Russia’s invasion of Ukraine in 2022 sparked widespread sanctions on Russian oil and led to a constraining global crude supply.

Praxis Precision Medicines jumped 13%. The genetic neuroscience company said the Food and Drug Administration had granted breakthrough therapy designation for ulixacaltamide, a treatment for patients with essential tremor. The designation will expedite development and regulatory review, the company said.

Shares of Ultragenyx Pharmaceutical and U.S.-listed shares of Mereo BioPharma cratered 42% and 88%, respectively. The companies said two Phase 3 trials for setrusumab to treat osteogenesis imperfecta, a rare bone disorder, didn’t meet their main goal of reducing fracture rates.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com, Adam Clark at adam.clark@barrons.com and Joe Woelfel at joseph.woelfel@barrons.com